Korean J Urol.  2008 Mar;49(3):237-241. 10.4111/kju.2008.49.3.237.

The Effect of Periurethral Prostatic Calculi on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia

• Cha WH
• Kim KH
• Seo YJ

• KMID: 1204625
• DOI: http://doi.org/10.4111/kju.2008.49.3.237

Abstract

PURPOSE: The aim of this study was to evaluate the effect of periurethral prostatic calculi on lower urinary tract symptoms(LUTS) at the initial visit and after treatment with an alpha-blocker in benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS
A total of 223 male patients with LUTS were studied. Group 1 consisted of 81 patients with periurethral prostatic calculi within 5 mm from the prostatic urethra of the transitional zone, as determined by transrectal ultrasound. Group 2 consisted of 142 patients without periurethral prostatic calculi within 5 mm from the prostatic urethra. The International Prostate Symptom Score(IPSS), maximal urinary flow rate (Qmax) and post voided residual urine(PVR) were measured in patients of both groups at the beginning of the study and at eight weeks after the treatment with 4 mg doxazosin gastrointestinal therapeutic system (GITS).
RESULTS
Voiding, storage and the total IPSS for Group 1 patients were higher than for Group 2 patients(p>0.05). Quality of life(QoL), Qmax, and PVR were not significantly different at the initial visit. After treatment with 4 mg doxazosin GITS, an improvement of voiding, storage and the total IPSS for Group 2 patients was seen as compared to Group 1 patients (p<0.05). The mean improvement of QoL was 0.44+/-0.73 for group 1 patients and 1.13+/-0.82 for group 2 patients(p<0.001). The mean change of Qmax was 1.02+/-1.40 ml/sec for Group 1 patients and 1.52+/-1.84ml/sec for Group 2 patients(p=0.035). Changes of PVR were not significant between the two groups.
CONCLUSIONS
This study suggests that the periurethral prostatic calculi may aggravate lower urinary tract symptoms and decrease the effect of alpha- blockers.

Keyword

Calculi; Symptoms; Prostatic hyperplasia

MeSH Terms

Male
Humans

Figure

• 

  Fig. 1. Periurethral prostatic calculi within 5mm from the prostatic urethra of the transitional zone were detected on transrectal ultrasonography (TRUS) findings, including more echogenic foci that caused acoustic shadowing as seen on a transverse view (A) and sagittal view (B) in Group 1 patients.

Reference

1. Chung TG, Chung JS, Lee MS, Ahn HJ. Prevalence of benign prostatic hyperplasia in Jeong-eup area: community-based study. Korean J Urol. 1999; 40:51–8.

2. Lepor H. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate Suppl. 1990; 3:75–84.

3. Caine M. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am. 1990; 17:641–9.

4. Moore RA. Morphology of prostatic corpora amylacea and calculi. Arch Pathol. 1936; 22:22–40.

5. Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004; 58:121–9.

6. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol. 1991; 145:984–7.

7. Cristol DS, Emmett JL. Incident of coincidence prostatic calculi, prostatic hyperplasia and carcinoma of prostate gland. JAMA. 1944; 124:646–7.

8. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol. 1982; 54:729–31.

9. Abrams P, Donovan JL, de la Rosette JJ, Schäfer W. International Continence Society “Benign Prostatic Hyperplasia” Study: background, aims, and methodology. Neurourol Urodyn. 1997; 16:79–91.

10. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992; 21:297–307.

11. Shapiro A, Mazouz B, Caine M. The alpha-adrenergic blocking effect of prazosin on the human prostate. Urol Res. 1981; 9:17–20.

12. Klimas R, Bennett B, Gardner WA Jr. Prostatic calculi: a review. Prostate. 1985; 7:91–6.

13. Sondergaard G, Vetner M, Christensen PO. Prostatic calculi. Acta Pathol Microbiol Immunol Scand. 1987; 95:141–5.

14. Shoskes DA, Lee CT, Murphy D, Kefer J, Wood HM. Incidence and significance of prostatic stones in men with chronic prostatitis/chronic pelvic pain syndrome. Urology. 2007; 70:235–8.

15. Young HD. Prostatic calculi. J Urol. 1934; 32:660–709.

16. Fox M. The natural history and significance of stone formation in the prostate gland. J Urol. 1963; 89:716–27.

17. Vilches J, Lopez A, De Palacio L, Muñoz C, Gomez J. SEM and X-ray microanalysis of human prostatic calculi. J Urol. 1982; 127:371–3.

18. Peeling WB, Griffiths GJ. Imaging of the prostate by ultrasound. J Urol. 1984; 132:217–24.

19. Schwinn DA, Michelotti GA. Alpha 1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000; 85(Suppl 2):6–11.

20. Elliott HL, Meredith PA, Reid JL. Pharmacokinetic overview of doxazosin. Am J Cardiol. 1987; 59:78G–81.

21. Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, et al. Doxazosin for benign prostatic hyperplasia: longterm efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol. 1997; 157:525–30.

22. Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Int J Urol. 2006; 13:1405–9.

23. Bedir S, Kilciler M, Akay O, Erdemir F, Avci A, Ozgök Y. Endoscopic treatment of multiple prostatic calculi causing urinary retention. Int J Urol. 2005; 12:693–5.

24. Minnery CH, Getzenberg RH. Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and ibuprofen. J Urol. 2005; 174:375–9.

25. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, et al. Expression and function of proinflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003; 56:171–82.